The findings provide support for potentially using aprocitentan in patients with BP that remains elevated despite treatment with three established antihypertensive drug classes and with stage 3 CKD.
Dapagliflozin became the first SGLT2 inhibitor approved for CKD alone just over 2 years ago, but uptake has lagged. Could a similar label gain for empagliflozin, plus a new recommendation, spark change?
Chronic kidney disease is associated with a more than sevenfold increase in the risk for sudden cardiac arrest among US residents of Hispanic or Latinx ethnicity, new data suggest.
Novo Nordisk will stop a trial studying Ozempic to treat kidney failure in patients with diabetes ahead of schedule because it was clear from an interim analysis that the treatment would succeed.